Discovery and identification of potential biomarkers of pediatric Acute Lymphoblastic Leukemia
Open Access
- 16 March 2009
- journal article
- research article
- Published by Springer Nature in Proteome Science
- Vol. 7 (1) , 7
Abstract
Background: Acute lymphoblastic leukemia (ALL) is a common form of cancer in children. Currently, bone marrow biopsy is used for diagnosis. Noninvasive biomarkers for the early diagnosis of pediatric ALL are urgently needed. The aim of this study was to discover potential protein biomarkers for pediatric ALL. Methods: Ninety-four pediatric ALL patients and 84 controls were randomly divided into a "training" set (45 ALL patients, 34 healthy controls) and a test set (49 ALL patients, 30 healthy controls and 30 pediatric acute myeloid leukemia (AML) patients). Serum proteomic profiles were measured using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy (SELDI-TOF-MS). A classification model was established by Biomarker Pattern Software (BPS). Candidate protein biomarkers were purified by HPLC, identified by LC-MS/MS and validated using ProteinChip immunoassays. Results: A total of 7 protein peaks (9290 m/z, 7769 m/z, 15110 m/z, 7564 m/z, 4469 m/z, 8937 m/z, 8137 m/z) were found with differential expression levels in the sera of pediatric ALL patients and controls using SELDI-TOF-MS and then analyzed by BPS to construct a classification model in the "training" set. The sensitivity and specificity of the model were found to be 91.8%, and 90.0%, respectively, in the test set. Two candidate protein peaks (7769 and 9290 m/z) were found to be down-regulated in ALL patients, where these were identified as platelet factor 4 (PF4) and pro-platelet basic protein precursor (PBP). Two other candidate protein peaks (8137 and 8937 m/z) were found up-regulated in the sera of ALL patients, and these were identified as fragments of the complement component 3a (C3a). Conclusion: Platelet factor (PF4), connective tissue activating peptide III (CTAP-III) and two fragments of C3a may be potential protein biomarkers of pediatric ALL and used to distinguish pediatric ALL patients from healthy controls and pediatric AML patients. Further studies with additional populations or using pre-diagnostic sera are needed to confirm the importance of these findings as diagnostic markers of pediatric ALL.Keywords
This publication has 35 references indexed in Scilit:
- Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV‐related hepatocellular carcinoma using a proteomics approachProteomics, 2006
- Proteomic‐based prediction of clinical behavior in adult acute lymphoblastic leukemiaCancer, 2006
- Proteomic analysis of childhood leukemiaLeukemia, 2005
- Conservation of unique cell-surface CD antigen mosaics in HIV-1–infected individualsBlood, 2005
- Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseasesHepatology, 2004
- Overexpression of Oncoprotein 18 Correlates with Poor Differentiation in Lung AdenocarcinomasMolecular & Cellular Proteomics, 2003
- Platelet chemokines and their receptors: what is their relevance to platelet storage and transfusion practice?Transfusion Medicine, 2001
- Structure and biology of complement protein C3, a connecting link between innate and acquired immunityImmunological Reviews, 2001
- Development of a Novel Proteomic Approach for the Detection of Transitional Cell Carcinoma of the Bladder in UrineThe American Journal of Pathology, 2001
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997